OTCMKTS:BAYRY Bayer Aktiengesellschaft (BAYRY) Stock Price, News & Analysis $12.30 -0.10 (-0.81%) As of 10/23/2026 03:59 PM Eastern Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartDividendEarningsNews and TrendsSEC FilingsShort Interest About Bayer Aktiengesellschaft Stock (OTCMKTS:BAYRY) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get BAYRY alerts:Sign Up Key Stats Today's Range$12.11▼$12.3250-Day Range$12.07▼$14.4652-Week Range$7.48▼$15.23Volume553,484 shsAverage Volume597,667 shsMarket Capitalization$48.34 billionP/E RatioN/ADividend Yield0.16%Price TargetN/AConsensus RatingBuy Company Overview Bayer Aktiengesellschaft is a Germany-based life sciences company headquartered in Leverkusen. Founded in 1863 by Friedrich Bayer and Johann Friedrich Weskott, the company develops products in health care and agriculture and serves customers in markets around the world. Bayer operates through three primary businesses: Pharmaceuticals, Consumer Health and Crop Science. Its Pharmaceuticals segment develops prescription medicines in areas such as cardiovascular disease, women’s health, oncology, hematology and specialty therapies. Consumer Health offers nonprescription products, including medicines, nutritional supplements and personal care brands. Through Crop Science, Bayer provides seeds, crop protection products and digital agricultural solutions intended to help farmers manage weeds, pests and diseases and improve agricultural productivity. The company’s portfolio includes products used across major crop categories and geographic regions. Bayer is led by Chief Executive Officer Bill Anderson.AI Generated. May Contain Errors. Read More Bayer Aktiengesellschaft Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks34th Percentile Overall ScoreBAYRY MarketRank™: 1.701999194955 of 5 starsBayer Aktiengesellschaft scored higher than 34% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion1.6 / 5Analyst RatingBuy Consensus RatingBayer Aktiengesellschaft has received a consensus rating of Buy. The company's average rating score is 3.13, and is based on 2 strong buy ratings, 5 buy ratings, 1 hold rating, and no sell ratings.Amount of Analyst CoverageBayer Aktiengesellschaft has received no research coverage in the past 90 days.Read more about Bayer Aktiengesellschaft's stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings Growth3.94% Earnings GrowthEarnings for Bayer Aktiengesellschaft are expected to grow by 3.94% in the coming year, from $1.27 to $1.32 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Bayer Aktiengesellschaft is -24.12, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Bayer Aktiengesellschaft is -24.12, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Growth RatioBayer Aktiengesellschaft has a PEG Ratio of 1.86. PEG Ratios above 1 indicate that a company could be overvalued.Price to Book Value per Share RatioBayer Aktiengesellschaft has a P/B Ratio of 1.64. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.Read more about Bayer Aktiengesellschaft's valuation and earnings. Short Interest3.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted0.01% of the float of Bayer Aktiengesellschaft has been sold short.Short Interest Ratio / Days to CoverBayer Aktiengesellschaft has a short interest ratio ("days to cover") of 0.44, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Bayer Aktiengesellschaft has recently increased by 15.14%, indicating that investor sentiment is decreasing significantly. Dividend0.8 / 5Dividend StrengthWeak Dividend YieldBayer Aktiengesellschaft has a dividend yield of 0.19%, which is in the bottom 25% of all stocks that pay dividends.Dividend GrowthBayer Aktiengesellschaft does not have a long track record of dividend growth.Dividend SustainabilityBased on earnings estimates, Bayer Aktiengesellschaft will have a dividend payout ratio of 1.52% next year. This indicates that Bayer Aktiengesellschaft will be able to sustain or increase its dividend.Read more about Bayer Aktiengesellschaft's dividend. News and Social Media3.6 / 5News Sentiment0.72 News SentimentBayer Aktiengesellschaft has a news sentiment score of 0.72. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.46 average news sentiment score of Healthcare companies.News Coverage This WeekMarketBeat has tracked 4 news articles for Bayer Aktiengesellschaft this week, compared to 5 articles on an average week.Search Interest13 people have searched for BAYRY on MarketBeat in the last 30 days. This is an increase of 44% compared to the previous 30 days.MarketBeat Follows1 people have added Bayer Aktiengesellschaft to their MarketBeat watchlist in the last 30 days. Company OwnershipN/AInsider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Bayer Aktiengesellschaft insiders have not sold or bought any company stock.Percentage Held by InstitutionsBayer Aktiengesellschaft has minimal institutional ownership at this time.Read more about Bayer Aktiengesellschaft's insider trading history. Receive BAYRY Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Bayer Aktiengesellschaft and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. BAYRY Stock News HeadlinesBayer Aktiengesellschaft - depositary receipt price target increased by 16.86% to $16.73October 23 at 7:23 PM | msn.comBayer Expands Real-World Kidney Data For Finerenone, Eyeing Long-Term Upside For BAYRYOctober 21, 2026 | tipranks.comThe investigation Porter spent tens of thousands to documentPorter Stansberry flew the Porter and Co. team 3,300 miles to Dublin to investigate a 17-year investing experiment called Project Prophet - and documented everything on film. Rooted in the laws of physics, this quantitative approach challenges conventional wealth-building wisdom. With 17 years of verified data behind it, Porter calls it unlike anything he has seen in nearly 30 years in the business.October 25 at 1:00 AM | Porter & Company (Ad)Bayer Advances Nurandociguat Tablet Study, Signaling Steady Progress in CKD PipelineOctober 19, 2026 | tipranks.comBayer to Present New Cardiac Amyloidosis and Heart Failure Data at the Heart Failure Society of America (HFSA) Annual Scientific MeetingOctober 8, 2026 | businesswire.comU.S. FDA Accepts Bayer's Supplemental New Drug Application for KERENDIA® (finerenone) to Treat Adults with Chronic Kidney Disease (CKD) Without DiabetesOctober 8, 2026 | businesswire.comBayer’s Real‑World Prostate Cancer Study Signals Key Trends for Treatment Adoption in CanadaOctober 6, 2026 | tipranks.comBayer to Invest $2.2 Billion in U.S. Pharma Manufacturing ExpansionOctober 2, 2026 | wsj.comSee More Headlines BAYRY Stock Analysis - Frequently Asked Questions How have BAYRY shares performed this year? Bayer Aktiengesellschaft's stock was trading at $10.82 at the beginning of the year. Since then, BAYRY shares have increased by 13.7% and is now trading at $12.30. How were Bayer Aktiengesellschaft's earnings last quarter? Bayer Aktiengesellschaft (OTCMKTS:BAYRY) released its quarterly earnings data on Tuesday, August, 4th. The company reported $0.29 EPS for the quarter, topping analysts' consensus estimates of $0.23 by $0.06. The company earned $12.53 billion during the quarter, compared to analyst estimates of $12.31 billion. Bayer Aktiengesellschaft had a positive trailing twelve-month return on equity of 16.77% and a negative net margin of 3.80%. Does Bayer Aktiengesellschaft have any subsidiaries? Bayer Aktiengesellschaft subsidiaries include these companies: Asklepios BioPharmaceutical, Care/of, KaNDy Therapeutics, BlueRock Therapeutics, Monsanto Company, Zoner.ag, Dihon Pharmaceutical, and more. How do I buy shares of Bayer Aktiengesellschaft? Shares of BAYRY stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Bayer Aktiengesellschaft own? Based on aggregate information from My MarketBeat watchlists, some other companies that Bayer Aktiengesellschaft investors own include Pfizer (PFE), NVIDIA (NVDA), ExxonMobil (XOM), Tesla (TSLA), Verizon Communications (VZ), Walt Disney (DIS) and Alibaba Group (BABA). Company Calendar Last Earnings8/04/2026Today10/25/2026Next Earnings (Estimated)11/03/2026Fiscal Year End12/31/2026Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeOTCMKTS SectorHealthcare Industry Pharmaceuticals Sub-IndustryPharmaceuticals Current SymbolOTCMKTS:BAYRY CIK1144145 Webwww.bayer.com Phone49214301Fax49-21-4306-6328Employees88,078Year Founded1863Profitability EPS (Trailing Twelve Months)($0.51) Trailing P/E RatioN/A Forward P/E Ratio9.69 P/E Growth1.86Net Income-$4.10 billion Net Margins-3.80% Pretax Margin-2.10% Return on Equity16.77% Return on Assets4.53% Debt Debt-to-Equity Ratio1.05 Current Ratio1.04 Quick Ratio0.67 Sales & Book Value Annual Sales$51.55 billion Price / Sales0.94 Cash Flow$2.18 per share Price / Cash Flow5.64 Book Value$7.50 per share Price / Book1.64Miscellaneous Outstanding Shares3,930,000,000Free FloatN/AMarket Cap$48.34 billion OptionableNot Optionable Beta0.57 Social Links 7 Stocks to Buy Before the Robotics RevolutionRobotics and automation are rapidly becoming essential infrastructure across healthcare, manufacturing, logistics, and many other industries. "Physical AI" is coming. Learn which seven companies are most positioned to benefit as intelligent robots enter the workforce.Get This Free Report This page (OTCMKTS:BAYRY) was last updated on 10/23/2026 by MarketBeat.com Staff. From Our PartnersThe investigation Porter spent tens of thousands to documentPorter Stansberry flew the Porter and Co. team 3,300 miles to Dublin to investigate a 17-year investing experi...Porter & Company | Sponsored$0. Later: $29.97.Bill Poulos is giving away his Simple Options Trading For Beginners book through a temporary link. Once that l...Profits Run | SponsoredThe $100 Stock Behind Elon's Next MoveA small, publicly traded supplier trading under $100 a share has reportedly worked alongside Elon Musk for mor...Paradigm Press | SponsoredEarth's biggest energy source: near Grand CanyonThe largest energy source on Earth contains 50,000 times every oil and gas reserve on the planet combined - an...Behind the Markets | SponsoredHe turned $12K into $1.65M without touching Apple or TeslaTim Sykes turned $12,415 in gift money into more than $1.65 million before graduating college, without trading...Tim Sykes | SponsoredBank of America: 'Digital Dollar Inevitable'Bank of America just revealed your expiration date. In their Bloomberg interview, they didn't just predict the...Decentralized Masters | SponsoredHere’s Why Trump Won’t End The Iran WarTrump has called an Iran deal close 38 times since the war began, yet the fighting keeps flaring back up. O...Banyan Hill Publishing | SponsoredFinancial legend: “This is bad, really bad...”Dr. Martin D. Weiss has publicly predicted six major American market crashes over his 55-year career, each war...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Bayer Aktiengesellschaft Please log in to your account or sign up in order to add this asset to your watchlist. Share Bayer Aktiengesellschaft With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.